CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

Study acronym: CENDIFOX
StatusUnknown
PhasePhase 1/2
SponsorAnup Kasi
Started

Record status This record was last updated December 17, 2024 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Aug 2024); last known: Active, Not Recruiting
  2. Primary completion date: Sep 2023 to Sep 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Sep 2025 to Sep 2026
    • Site details revised at 3 of 3 sites
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2021 to Oct 20, 2021
    • Site details revised at 3 of 3 sites
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase IB/IIA trial to ensure the safety of Certepetide (LSTA1/CEND-1) in combination with with Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal cancers
Trial Details
NCT Number NCT05121038
Lead Sponsor Anup Kasi
Collaborators: Cend Therapeutics Inc.
Conditions
(from sponsor)		 Colon Cancer, Pancreas Cancer, Digestive Cancer
Related terms Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov